Trade

with

OncoMed Pharmaceuticals Inc
(NASDAQ: OMED)
AdChoices
19.21
-0.29
-1.49%
After Hours :
19.21
0.00
0.00%

Open

19.68

Previous Close

19.50

Volume (Avg)

139.20k (178.28k)

Day's Range

18.90-19.97

52Wk Range

12.07-42.34

Market Cap.

571.71M

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

29.76M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 37.78M

    • Net Income

    • -26.07M

    • Market Cap.

    • 571.71M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -84.87

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -

    • Price/Sales

    • 12.14

    • Price/Book Value

    • 6.19

    • Price/Cash flow

    • 4.94

      • EBITDA

      • -22.75M

      • Return on Capital %

      • -21.28

      • Return on Equity %

      • -

      • Return on Assets %

      • -21.28

      • Book Value/Share

      • 3.10

      • Shares Outstanding

      • 29.76M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 105.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -80.45

            • 39.38

            • Net Profit Margin

            • -84.87

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.34

              • 2.92

              • Quick Ratio

              • 5.29

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 3.08

              • 2.21

              • Book Value/Share

              • 3.10

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -13.79

                • 238.10

                • P/E Ratio 5-Year High

                • -31.50

                • 634.30

                • P/E Ratio 5-Year Low

                • -8.98

                • 124.82

                • Price/Sales Ratio

                • 11.70

                • 8.94

                • Price/Book Value

                • 5.97

                • 8.12

                • Price/Cash Flow Ratio

                • 4.94

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -21.28

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.25

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -23.90M
                  Operating Margin
                  -63.26
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  4.94
                  Ownership

                  Institutional Ownership

                  81.21%

                  Top 10 Institutions

                  69.50%

                  Mutual Fund Ownership

                  14.30%

                  Float

                  44.70%

                  5% / Insider Ownership

                  1.04%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Pictet-Biotech

                  •  

                    859,668

                  • 14.93

                  • 3.28

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    731,932

                  • 0.00

                  • 2.46

                  • iShares Nasdaq Biotechnology

                  •  

                    397,849

                  • 3.08

                  • 1.38

                  • iShares Russell 2000 (AU)

                  •  

                    201,609

                  • -1.02

                  • 0.70

                  • PrimeCap Odyssey Aggressive Growth Fund

                  •  

                    159,100

                  • -2.15

                  • 0.53

                  • Franklin Biotechnology Discovery

                  •  

                    145,100

                  • 0.00

                  • 0.49

                  • Vanguard Total Stock Mkt Idx

                  •  

                    142,524

                  • 14.64

                  • 0.48

                  • Pictet-Global Megatrend Selection

                  •  

                    132,911

                  • 14.37

                  • 0.51

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    120,434

                  • 0.00

                  • 0.40

                  • Candriam Eqs L Biotechnology

                  •  

                    108,000

                  • 0.00

                  • 0.36

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Sectoral Asset Management Inc

                  •  

                    1,392,485

                  • +3.33%

                  • 4.68

                  • Fidelity Management and Research Company

                  •  

                    852,366

                  • +339.14%

                  • 2.87

                  • Bvf Inc

                  •  

                    825,647

                  • -16.58%

                  • 2.78

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  -

                  OncoMed Pharmaceuticals Inc was incorporated in July 2004 in Delaware. The Company is a clinical development-stage biotechnology company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting ...morecancer stem cells. The Company’s operations are based in Redwood City, California. On July 17, 2013, the Company’s registration statement on Form S-1 (File No. 333-181331) relating to the initial public offering of its common stock was declared effective by the SEC. The Company has five anti-CSC product candidates in clinical development. Additionally, other antibodies are in preclinical development with Investigational New Drug filings planned for as early as late 2014 or 2015. The first candidate, demcizumab, has completed a single-agent Phase Ia safety and dose escala...moretion trial and is currently in Phase Ib combination therapy trials in patients with non-small cell lung cancer and pancreatic cancer and a Phase Ib/II trial combining demcizumab with paclitaxel in ovarian cancer. The second candidate, anti-Notch2/3 (OMP-59R5), is in a Phase Ib/II trial in pancreatic cancer in combination therapy with gemcitabine and Abraxane and a second Phase Ib/II trial in small cell lung cancer in combination therapy with etoposide and cisplatin chemotherapy. The third candidate, vantictumab (OMP-18R5), continues in a single-agent Phase Ia trial, and the Company has recently initiated three separate Phase Ib combination trials, one trial each in patients with breast cancer, pancreatic cancer, and non-small-cell lung cancer. The fourth candidate, Fzd8-Fc (OMP-54F28), is in a single-agent Phase Ia safety and dose escalation trial in solid tumor malignancies, and has begun three Phase Ib trials, one trial in each of pancreatic cancer, ovarian cancer, and hepatocellular carcinoma, of OMP-54F28 in combination with standard-of-care therapies. The fifth candidate, anti-Notch1 (OMP-52M51), is in two single-agent Phase Ia safety and dose escalation trials in hematologic and solid tumor malignancies.The Company purchases quantities of its product candidates from its contract manufacturers pursuant to purchase orders that it places from time to time. It competes in the segments of the pharmaceutical, biotechnology and other related markets that address solid tumor cancers and hematologic cancers. It also faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements on the clinical development, manufacture, marketing and distribution of its product candidates.lessless

                  Key People

                  Paul J. Hastings

                  CEO/Chairman of the Board/Director/President

                  Mr. Sunil Patel

                  CFO/Chief Accounting Officer/Senior VP, Divisional

                  Dr. John A. Lewicki, PhD

                  Chief Scientific Officer/Executive VP

                  Dr. Alicia J. Hager, PhD

                  General Counsel/Vice President

                  Michael S. Wyzga

                  Director

                  • OncoMed Pharmaceuticals Inc

                  • 800 Chesapeake Drive

                  • Redwood City, CA 94063

                  • USA.Map

                  • Phone: +1 650 995-8200

                  • Fax: +1 650 995-8600

                  • oncomed.com

                  Incorporated

                  2004

                  Employees

                  91

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: